61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 61,957 Glaukos shares worth approximately $8.7 million, joining other institutional investors; institutions now own 99.04% of the company.
• Glaukos reported strong quarterly growth, with revenue rising 49.6% year over year to $185.6 million and a smaller-than-expected loss of $0.14 per share. The company remains unprofitable, however.
• Analyst sentiment remains bullish, with multiple firms raising price targets and the stock carrying a “Moderate Buy” consensus rating, although insiders have sold roughly $19.6 million of shares over the past three months.

Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE:GKOS - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier's stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of Glaukos during the fourth quarter worth approximately $28,000. Larson Financial Group LLC lifted its position in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 132 shares during the period. Parallel Advisors LLC lifted its position in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 226 shares during the period. Farther Finance Advisors LLC grew its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier's stock worth $46,000 after buying an additional 215 shares in the last quarter. Finally, CWM LLC grew its stake in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock worth $80,000 after buying an additional 143 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Trading Up 0.4%

GKOS opened at $185.66 on Monday. The company's 50 day moving average is $157.38 and its 200-day moving average is $131.72. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a market cap of $10.95 billion, a P/E ratio of -57.13 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm's revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.24) EPS. Equities research analysts predict that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on GKOS. Stifel Nicolaus boosted their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Needham & Company LLC increased their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Piper Sandler reissued an "overweight" rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research note on Thursday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Thursday, April 30th. Finally, UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They set a "neutral" rating and a $150.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $178.08.

Insider Activity at Glaukos

In other news, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares of the company's stock, valued at $7,107,140. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 113,025 shares of company stock worth $19,600,006. Corporate insiders own 5.90% of the company's stock.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source